| Not Yet Recruiting | Ravulizumab Outcomes in Polish Patients With aHUS NCT07399730 | AstraZeneca | — |
| Recruiting | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS NCT07308574 | Alexion Pharmaceuticals, Inc. | Phase 4 |
| Recruiting | The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hosp NCT07218536 | AstraZeneca | — |
| Recruiting | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants NCT05935215 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases NCT05996731 | Mario Negri Institute for Pharmacological Research | N/A |
| Recruiting | Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy NCT05805202 | Mario Negri Institute for Pharmacological Research | N/A |
| Active Not Recruiting | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to C NCT04889430 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Part NCT04958265 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adol NCT04861259 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Eculizumab to Cemdisiran Switch in aHUS NCT03999840 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | Observational Study of Elizaria® in aHUS Patients NCT04749810 | AO GENERIUM | — |
| Unknown | TTP and aHUS in Complicated Pregnancies NCT03605511 | University College, London | — |
| Completed | Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ D NCT03518203 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Terminated | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome NCT03205995 | Omeros Corporation | Phase 3 |
| Unknown | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series NCT03574506 | Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia | — |
| Withdrawn | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome NCT03303313 | Alnylam Pharmaceuticals | Phase 2 |
| Withdrawn | The Role of Microparticles as a Biomarker NCT02626663 | University of Rochester | — |
| Terminated | Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndr NCT02614898 | Alexion Pharmaceuticals, Inc. | — |
| Completed | Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS NCT02574403 | Nantes University Hospital | Phase 4 |
| Terminated | Complement Inhibition in aHUS Dialysis Patients NCT02464891 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Recruiting | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry NCT01522183 | Alexion Pharmaceuticals, Inc. | — |
| Terminated | aHUS Observational Long Term Follow-Up NCT01522170 | Alexion Pharmaceuticals, Inc. | — |
| Completed | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic NCT01193348 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Synd NCT01194973 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic U NCT00838513 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS NCT00844428 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS NCT00844545 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS NCT00844844 | Alexion Pharmaceuticals, Inc. | Phase 2 |